On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent Opdivo as adjuvant treatment after surgery. The approval is based on results from the CheckMate-77T trial, the company’s second Phase 3 trial wi
The latest trading day saw Bristol Myers Squibb (BMY) settling at $54.20, representing a +0.82% change from its previous close.
A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?